China's 2026 Drug Access Reforms: How NRDL Expansion and Hospital Access Policies Could Reshape Pharmaceutical Revenue Opportunities
China · Pharmaceutical Market Access · 2026

China's 2026 Drug Access Reforms: How NRDL Expansion and Hospital Access Policies Could Reshape Pharmaceutical Revenue Opportunities

China's pharmaceutical market is entering a significant phase of market access transformation. In November 2026, the government announced an expanded National Reimbursement Drug List (NRDL), a broader Commercial Health Insurance Innovative Drug List (CHIIDL), and new measures designed to improve the availability of innovative medicines in hospitals.

Together, these developments address two longstanding commercial challenges for pharmaceutical companies: obtaining reimbursement coverage and converting that coverage into actual patient access.

The 2026 NRDL adds 107 medicines, including 51 Class 1 innovative drugs. Meanwhile, the commercial insurance list adds 12 innovative medicines, bringing its total to 28. Both revised lists will take effect on January 1, 2027.

For pharmaceutical manufacturers, biotechnology companies and investors, the implications extend beyond reimbursement. Hospital formulary access, physician adoption, patient affordability and pricing negotiations will increasingly determine the commercial performance of innovative therapies in China.

107Medicines added to the 2026 NRDL
51Class 1 innovative drugs included
3,331Medicines in the updated national catalogue
1 Jan 2027Effective date for the revised lists
APOTHIUM AI · MARKET ACCESS INTELLIGENCE

1. China's 2026 NRDL Expansion: A New Opportunity for Innovative Medicines

China's National Healthcare Security Administration (NHSA) announced 107 additions to the 2026 National Reimbursement Drug List, including 51 Class 1 innovative drugs.

Following the adjustment, the national reimbursement catalogue contains 3,331 medicines. The additions cover several important therapeutic areas, including oncology, rare diseases, chronic conditions and mental health.

One particularly significant development is the inclusion of a CAR-T therapy for lymphoma in China's national basic medical insurance list. The commercial insurance list separately includes the world's first CAR-T therapy for solid tumours and China's first gene therapy for haemophilia B.

These developments highlight the growing importance of reimbursement pathways for advanced therapies that have historically faced substantial affordability barriers.

Key 2026 NRDL developments:

  • 107 newly added medicines.
  • 51 Class 1 innovative drugs.
  • 3,331 medicines in the updated national catalogue.
  • First CAR-T therapy for lymphoma included in national basic medical insurance.
  • 12 additional medicines included in the commercial insurance list.
  • Revised reimbursement coverage effective January 1, 2027.

The expansion demonstrates China's continued effort to balance pharmaceutical innovation with healthcare affordability and insurance fund sustainability.

APOTHIUM AI · MARKET ACCESS INTELLIGENCE

2. Commercial Health Insurance Expands Access to High-Value Therapies

Alongside the NRDL, China expanded its Commercial Health Insurance Innovative Drug List by adding 12 medicines, bringing the total to 28.

This list is particularly relevant for innovative treatments that may face affordability challenges under conventional reimbursement arrangements.

The 2026 additions include advanced cell and gene therapies, including a CAR-T treatment for solid tumours and a gene therapy for haemophilia B.

For biotechnology companies developing cell and gene therapies, commercial insurance provides an additional pathway to address the gap between innovative treatment development and patient affordability.

This creates opportunities for pharmaceutical companies to evaluate multiple reimbursement and payment strategies rather than relying exclusively on national basic medical insurance.

APOTHIUM AI · MARKET ACCESS INTELLIGENCE

3. Hospital Access Reforms: Connecting Reimbursement with Actual Drug Adoption

Reimbursement inclusion does not automatically guarantee hospital availability.

Pharmaceutical manufacturers have historically faced additional challenges involving hospital formulary approvals, procurement processes, prescribing restrictions and payment mechanisms.

China's October 30, 2026, hospital access notice, issued by four national authorities, addresses several of these barriers.

The policy directs secondary-level and higher medical institutions to improve their procedures for adding innovative medicines to hospital formularies and to convene Pharmacy Administration and Drug Therapeutics Committee meetings in a timely manner.

For eligible Class 1 innovative medicines included in the two national lists, the policy introduces additional flexibility.

Key measures include:

  • Faster formulary consideration: Hospitals are encouraged to review and incorporate eligible innovative medicines based on clinical needs and institutional capabilities.
  • Reduced specification restrictions: Eligible Class 1 innovative medicines are excluded from the conventional one-product, two-specification restriction.
  • Performance assessment flexibility: These medicines are excluded from specified public hospital performance indicators relating to basic medicine utilisation and average drug expenditure.
  • Payment flexibility: Certain cases involving commercial insurance list medicines can receive alternative treatment under disease-based payment arrangements following the prescribed review process.
  • Improved clinical awareness: Healthcare authorities are encouraging training, expert guidance and clinical evidence development.

These measures are important because they address the operational barriers between reimbursement approval and actual prescribing.

APOTHIUM AI · MARKET ACCESS INTELLIGENCE

4. Pharmaceutical Revenue Opportunities: Where Could Companies Benefit?

The combined reimbursement and hospital access reforms could influence pharmaceutical revenue through three interconnected channels.

A. Higher patient accessibility

NRDL inclusion can reduce patients' out-of-pocket treatment costs, potentially increasing the eligible patient population able to access a medicine.

For manufacturers, the commercial opportunity depends on the relationship between treatment affordability, patient eligibility, reimbursement conditions and prescribing behaviour.

B. Greater hospital penetration

Hospital formulary access is a critical step in translating reimbursement coverage into commercial uptake.

Companies that establish relationships with hospital decision-makers, clinical specialists and pharmacy committees before reimbursement implementation may be better positioned to support timely adoption.

C. Additional commercial insurance pathways

The expanded commercial insurance list provides another potential route for high-value innovative medicines, particularly therapies with substantial treatment costs.

This may be relevant to oncology, rare diseases and advanced cell and gene therapies.

An important commercial consideration is that increased patient volume does not necessarily translate into equivalent revenue growth. NRDL negotiations, reimbursement payment standards, treatment eligibility and manufacturer pricing decisions can influence the net revenue generated per patient.

APOTHIUM AI · MARKET ACCESS INTELLIGENCE

5. What the Early Commercial Data Indicates

China's experience with its initial commercial insurance innovative drug programme provides an early indication of how institutional availability can influence commercial performance.

According to figures reported by the Economic Observer and NHSA in November 2026, by the end of October:

  • 18 medicines had been made available across approximately 1,710 medical institutions and designated retail pharmacies.
  • Nearly 30,000 patients had used these medicines.
  • Associated drug sales were approximately RMB 600 million.
  • The number of institutions stocking these medicines had increased by approximately 140%.
  • Monthly sales had increased by approximately 70% compared with the period before inclusion.

These figures provide an important indication that improved availability and reimbursement pathways can support commercial uptake.

However, they represent reported programme-level results from the earlier commercial insurance list and should not be interpreted as the revenue growth rate of every newly listed medicine or pharmaceutical company.

For manufacturers, the next challenge is translating policy-driven access into sustainable product-level revenue while maintaining commercial viability.

APOTHIUM AI · MARKET ACCESS INTELLIGENCE

6. Strategic Implications for Pharmaceutical and Biotechnology Companies

The November 2026 developments suggest that market access planning in China needs to begin well before reimbursement decisions are announced.

Regulatory and launch planning: Companies should evaluate China regulatory filing timelines and the potential commercial implications of qualifying as a Class 1 innovative drug.

KOL and hospital engagement: Medical Affairs teams should identify relevant clinical experts, hospital decision-makers and therapeutic-area specialists before reimbursement implementation.

Pricing and reimbursement strategy: Manufacturers need to evaluate reimbursement negotiations, commercial insurance opportunities, patient affordability and net revenue implications together.

Competitive intelligence: Companies should monitor competitor reimbursement status, hospital formulary adoption, clinical evidence and treatment uptake to identify market opportunities.

Commercial forecasting: Pharmaceutical leaders should model different scenarios involving patient eligibility, treatment penetration, reimbursement levels, pricing changes and competitor entry.

For multinational pharmaceutical companies, these considerations are particularly important when planning global launch sequencing and regional commercial strategies.

APOTHIUM AI · MARKET ACCESS INTELLIGENCE

7. The Role of AI-Driven Intelligence in Pharmaceutical Market Access

As reimbursement policies and hospital access requirements become increasingly interconnected, pharmaceutical companies need a more integrated approach to market intelligence.

AI-driven intelligence can help organisations analyse regulatory announcements, reimbursement developments, competitive movements, clinical evidence and stakeholder perspectives across multiple markets.

However, policy monitoring alone is insufficient. Commercial teams also need to understand how physicians, payers, hospital decision-makers and patients interpret these changes.

An integrated intelligence approach can support:

  • Continuous monitoring of reimbursement and policy developments.
  • Competitive tracking of innovative drug launches and market access decisions.
  • Identification of potential hospital adoption barriers.
  • Analysis of payer and stakeholder expectations.
  • Assessment of patient segments and commercial opportunities.
  • Expert validation of strategic assumptions.

Apothium AI combines AI-powered analysis with human expertise and expert validation to support complex life sciences decisions.

Explore Apothium AI's Market and Competitive Intelligence capabilities and its Commercial Strategy Intelligence solutions for pharmaceutical market assessment, competitive positioning and launch planning.

APOTHIUM AI · MARKET ACCESS INTELLIGENCE

8. Outlook: From Reimbursement Inclusion to Sustainable Commercial Growth

China's 2026 pharmaceutical access reforms represent a broader shift towards connecting reimbursement policy, hospital availability and innovative medicine adoption.

The expanded NRDL and commercial insurance list create additional access pathways, while hospital-level reforms seek to reduce operational barriers to prescribing and procurement.

Nevertheless, reimbursement inclusion is only one component of commercial success. Manufacturers must also address pricing pressure, clinical evidence requirements, hospital adoption, physician awareness and supply reliability.

As the revised lists take effect in January 2027, pharmaceutical companies will need to monitor how these policies translate into patient access, institutional availability and actual product sales.

The central commercial question is no longer simply whether an innovative medicine can secure reimbursement in China, but how effectively manufacturers can convert reimbursement access into sustainable patient reach and revenue growth.


APOTHIUM AI · MARKET ACCESS INTELLIGENCE

About Apothium AI

Apothium AI brings together artificial intelligence, primary research and expert intelligence to support pharmaceutical and biotechnology organisations in making informed clinical and commercial decisions.

Through AI-driven insight generation, market and competitive intelligence, KOL intelligence and commercial strategy capabilities, Apothium AI helps life sciences teams navigate complex markets and identify emerging opportunities.

Explore Apothium AI to learn more about its intelligence capabilities.

Explore our capabilities: Market & Competitive Intelligence | Commercial Strategy Intelligence | AI-Driven Insight Generation

Get Started

Make Better Decisions with Trusted Intelligence

If your organization requires insights that are not just fast, but accurate, validated, and decision-ready, Apothium AI is built to support you.

Human and AI collaboration for validated life sciences intelligence